DrugPatentWatch Database Preview
Drugs in Development Information for Alisertib
Drug Development Status for Alisertib: Patents, clinical trial progress, indications
Alisertib is an investigational drug.
There have been 47 clinical trials for Alisertib.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2012.
The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and Takeda.
There are fifteen US patents protecting this investigational drug and one hundred and ninety-four international patents.
Summary for Alisertib
| US Patents | 15 |
| International Patents | 194 |
| US Patent Applications | 41 |
| WIPO Patent Applications | 19 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2012-06-01) |
| Vendors | 70 |
Recent Clinical Trials for Alisertib
| Title | Sponsor | Phase |
|---|---|---|
| Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer | Takeda | Phase 1 |
| Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer | Collin Blakely | Phase 1 |
| Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL | Columbia University | Phase 3 |
Clinical Trial Summary for Alisertib
Top disease conditions for Alisertib
Top clinical trial sponsors for Alisertib
US Patents for Alisertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Alisertib | Start Trial | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate | Millennium Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| Alisertib | Start Trial | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | Oryzon Genomics, S.A. (Madrid, ES) | Start Trial |
| Alisertib | Start Trial | Aurora kinase inhibitors for inhibiting mitotic progression | Millennium Pharmaceuticials, Inc. (Cambridge, MA) | Start Trial |
| Alisertib | Start Trial | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin- -2-yl]amino}-2-methoxybenzoate | Millennium Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| Alisertib | Start Trial | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | Millennium Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| Alisertib | Start Trial | Solid pharmaceutical compositions and processes for their production | MILLENNIUM PHARMACEUTICALS, INC. (Cambridge, MA) | Start Trial |
| Alisertib | Start Trial | Tetrazolones as a carboxylic acid bioisosteres | Rigel Pharmaceuticals, Inc. (South San Francisco, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Alisertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Alisertib | Brazil | 112012020557 | 2030-02-19 | Start Trial |
| Alisertib | Canada | 2788774 | 2030-02-19 | Start Trial |
| Alisertib | China | 102770024 | 2030-02-19 | Start Trial |
| Alisertib | China | 104031049 | 2030-02-19 | Start Trial |
| Alisertib | European Patent Office | 2536279 | 2030-02-19 | Start Trial |
| Alisertib | Japan | 2013520424 | 2030-02-19 | Start Trial |
| Alisertib | Japan | 2015180679 | 2030-02-19 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
